James Mc Leod is a physician scientist and pharmaceutical executive with over 25 years of experience spanning preclinical and the phases of clinical development. Prior to joining InxMed, he was Chief Medical Officer and Senior VP at Galleon Pharmaceuticals and a consultant to small biotechnology companies and medical research foundations. He has headed the Experimental Medicine group at Merck Research Laboratories and the Early Clinical Research and Experimental Medicine group at the Schering-Plough Research Institute (SPRI).  He joined SPRI from Novartis in 2004, where he headed the Clinical Pharmacology, Experimental Clinical Pharmacology and Translational Medicine groups. He has extensive clinical development experience with individual or group leadership of 24 new drug approvals globally spanning all major therapeutic areas including gastroenterology and oncology medications.  James has degrees in Biomedical and Chemical Engineering (Rensselaer Polytechnic Institute) and Medicine (University of Connecticut) was medically boarded in internal medicine and endocrinology and metabolism. He has been a fellow in the Endocrinology & Metabolism and Human Genetics and has held faculty positions at the University of Pennsylvania and Northwestern University medical schools. He has been a member of ICH working groups and has co-chaired PhRMA and IQ Consortium innovation initiatives. He is a past chair of the PhRMA Clinical Pharmacology Technical Group.